MedTrace Logo

Study of Gammalinolenic Acid for Juvenile Rheumatoid Arthritis

NCT00004420 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-03-25

No results posted yet for this study

Summary

OBJECTIVES:

I. Determine the efficacy and safety of gammalinolenic acid in the treatment of childhood arthritis.

Conditions

  • Juvenile Rheumatoid Arthritis

Interventions

DRUG

gamma-Linolenic acid

Sponsors & Collaborators

  • University of Massachusetts, Worcester

    collaborator OTHER

  • FDA Office of Orphan Products Development

    lead FED

Principal Investigators

  • Robert B. Zurier · University of Massachusetts, Worcester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
1 Year
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-09-30
Completion
1999-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004420 on ClinicalTrials.gov